Exploring how epigenetics and non-coding RNA affect leukemia
Official title: Integration of epigenetic and non-coding RNA mechanism in leukemia
Funded at Thomas Jefferson University · NIH-10917025 · Data updated 2026-11-12
This study is looking at how certain changes in our genes and tiny RNA molecules might affect the development of acute myeloid leukemia (AML) and how the disease responds to treatment, with the hope that this research will help create better, more personalized therapies for patients like you.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $339,008 |
| NIH project number | 5R37CA226433-07 |
| Project ID | NIH-10917025 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with acute myeloid leukemia, both children and adults.
✕Less likely to help
Patients with leukemia types other than acute myeloid leukemia may not receive direct benefits from this research.
What this research studies
This research investigates the roles of epigenetic modifications and non-coding RNA in the development and progression of leukemia, particularly acute myeloid leukemia (AML). By utilizing advanced techniques such as CRISPR, the study aims to understand how these molecular mechanisms contribute to the disease and its resistance to treatment. Patients may benefit from insights gained that could lead to more effective therapies tailored to their specific genetic and epigenetic profiles.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that improve outcomes for leukemia patients.
How similar studies have gone: Previous research has shown promising results in understanding the role of epigenetics in cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Thomas Jefferson University
Philadelphia, United States Active
Researchers
- Principal investigator: Meyer, Sara E — Thomas Jefferson University
- Study coordinator: Meyer, Sara E
Related research
Other NIH-funded projects on the same topics.
-
Investigating a specific type of leukemia in children caused by genetic changes.
This study is looking at how certain proteins linked to leukemia affect kids and teens with high-risk blood cancers, and the researchers hope to find new ways to treat these conditions by learning more about how the disease works.
-
Caregiver-led mobile tool to support healthy habits for kids treated for ALL
A caregiver-directed mobile program helps children who were treated for acute lymphoblastic leukemia build healthier daily routines.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Understanding TCRs in Leukemia to Improve Immunotherapies
A short, patient-friendly look at a project trying to map how immune cells recognize leukemia so future therapies can be better and safer for people with AML.
-
Targeted therapy for AML using DHODH inhibitors to boost differentiation and immune response
Aims to help adults with acute myeloid leukemia by using a special drug approach that makes cancer cells act more like normal blood cells and supports the immune system.
-
Genomics of childhood ALL across global populations
A wide-ranging study looks at how inherited genetics influence the risk of childhood acute lymphoblastic leukemia around the world.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.